Sean Pokorney, MD, director of the arrhythmia core lab, Duke Clinical Research Institute, assistant professor of Medicine, Duke University, discusses a late-breaking ACC 2022 study that shows mortality is higher in patients with implantable electrophysiology (EP) device infections where the leads are not explanted.

Santiago Garcia, MD, lead author of the study and director of the structural heart program at The Christ Hospital in Cincinnati, Ohio, presented new data from the North American COVID-19 STEMI (NACMI) registry at ACC.22. Severity of heart attacks were reduced in vaccinated patients, with zero deaths in vaccinated patients in 2021.

Joanna Chikwe, MD, founding chair of the department of cardiac surgery at Cedars-Sinai Hospital, compares transcatheter edge-to-edge repair (TEER) to mitral valve surgery for primary mitral regurgitation.

Steven E. Nissen, MD, chief academic officer of the Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute at the Cleveland Clinic, was the lead author on the Apollo Trial, a late-breaking ACC.22 study evaluating the effectiveness of an mRNA drug to suppress lipoprotein(a).

Click through a wide variety of snapshots from ACC.22 in Washington, D.C. 

An updated look at patients treated with Medtronic's renal denervation system was presented at ACC.22 and simultaneously published in The Lancet. 

Read our in-person coverage of the final day of ACC.22.

New results from the North American COVID-19 STEMI (NACMI) registry showed a 25% reduction in early mortality in 2021 compared to 2020 among STEMI patients with a confirmed COVID-19 infection.